Alignment Healthcare, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Alignment Healthcare (ALHC) director and EVP Joseph Konowiecki filed a Rule 144 notice to sell 26,000 shares, valued at $226,460, to cover tax obligations on vested equity awards. The sale is scheduled for September 17, 2026, and is not discretionary. Konowiecki also reported prior sales of 75,000 shares under a 10b5-1 plan.
Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.
Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning ALHC (Alignment Healthcare, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 8 bearish.
Recent ALHC coverage spans financial news, market movers and insider activity.
In the last 30 days, ALHC insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($9.0M). The most active reporter was KAO JOHN E, Chief Executive Officer, with 3 filings. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.
Minor dilution from insider sale; limited price impact.
Significant margin pressure expected for insurers heavily weighted to Medicare Advantage.
Significant intraday sell-off driven by lack of guidance on star ratings.
Operational challenges hurt sentiment, but guidance unchanged.
The unexpected investment announcement triggered a sharp sell‑off, indicating short‑term downside pressure.
AlphAI scores every news story that mentions ALHC with an AI model for sentiment and relevance, and aggregates insider trades from Alignment Healthcare, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alignment Healthcare (ALHC) director and EVP Joseph Konowiecki filed a Rule 144 notice to sell 26,000 shares, valued at $226,460, to cover tax obligations on vested equity awards. The sale is scheduled for September 17, 2026, and is not discretionary. Konowiecki also reported prior sales of 75,000 shares under a 10b5-1 plan.
1 min readSeveral healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.
2 min readAlignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.
2 min readSkyworks Solutions (SWKS) and Qorvo (QRVO) rose 10% and 7% respectively, recovering from prior sell-offs. Axon (AXON) fell 9% after a $1B convertible note sale. Revvity (RVTY) jumped 7% to a 52-week high, citing strong backlog. Dave & Buster's (PLAY) dropped 17% after missing Q2 revenue and EBITDA estimates. Enova (ENVA) tumbled 25% after withdrawing a regulatory application. Sysco (SYY) slid 3% on a 12.3M share offering. Alignment Healthcare (ALHC) fell 18% due to business headwinds. Waystar (W
2 min readAlignment Healthcare (ALHC) shares dropped 18% to a 52-week low after presenting at the Baird 2026 Global Healthcare Conference, disclosing a $10M-$11M investment for the second quarter. The decline reflects investor reaction to the company's updated financial outlook.
1 min readAlignment Healthcare (ALHC) shares fell after analysts reduced price targets and one downgraded the stock, reflecting lower near-term confidence. Goldman Sachs maintained its Buy rating. The company reports steady growth in members and revenue, but faces risks from thin margins and higher-cost patients. Potential medical expense spikes or policy changes could impact earnings.
1 min readAlignment Healthcare (ALHC) CEO John E. Kao sold 557,870 shares. On September 11, 2026, he sold 385,270 shares at $12.68 per share to cover tax obligations. On September 10, 2026, a trust associated with Kao sold 172,600 shares at $12.96 per share under a 10b5-1 trading plan. Kao held 1,223,473 shares directly and 618,166 shares indirectly post-sales.
2 min readAlignment Healthcare's President, Maroney Dawn Christine, sold 122,661 shares at $12.68 each, totaling $1.56M, to cover taxes on vested restricted stock units. She retains 794,606 shares.
1 min readMaroney Dawn Christine (President) sold 122,707 shares of Alignment Healthcare, Inc. (ALHC) at $12.68 ($1.56M total) on 2026-09-11.
1 min readKAO JOHN E (Chief Executive Officer) sold 385,270 shares of Alignment Healthcare, Inc. (ALHC) at $12.68 ($4.89M total) on 2026-09-11 under a Rule 10b5-1 trading plan.
1 min read
